We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

30 hedge funds and large institutions have $174M invested in Crescent Biopharma in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,587% more capital invested

Capital invested by funds: $6.46M → $174M (+$167M)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

16.18% more ownership

Funds ownership: 0.48% → 16.66% (+16%)

14% less funds holding

Funds holding: 35 → 30 (-5)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

Holders
30
Holders Change
-5
Holders Change %
-14.29%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
9
Reduced
5
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$29.9M
2
FFM
Fairmount Funds Management
Pennsylvania
+$29.4M
3
VA
VR Adviser
New York
+$28.7M
4
BI
BVF Inc
California
+$27.3M
5
PBA
Paradigm Biocapital Advisors
New York
+$13.6M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$561K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$120K
3
UBS Group
UBS Group
Switzerland
-$93.8K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$80.3K
5
SC
Shay Capital
New York
-$74.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$22.8M +$29.9M +1,414,190 New
FFM
2
Fairmount Funds Management
Pennsylvania
$22.4M +$29.4M +1,387,866 New
VA
3
VR Adviser
New York
$22.4M +$28.7M +1,357,864 +4,526%
BI
4
BVF Inc
California
$22.4M +$27.3M +1,292,420 +1,354%
PBA
5
Paradigm Biocapital Advisors
New York
$10.4M +$13.6M +642,721 New
LGM
6
Logos Global Management
California
$8.94M +$10.6M +499,686 +925%
BCM
7
Boxer Capital Management
California
$7.32M +$9.6M +453,686 New
CC
8
Commodore Capital
New York
$7.32M +$9.6M +453,686 New
DTC
9
Deep Track Capital
Connecticut
$7.32M +$9.6M +453,686 New
PA
10
Perceptive Advisors
New York
$7.32M +$9.6M +453,686 New
FLSM
11
Frazier Life Sciences Management
California
$7.32M +$9.6M +453,685 New
SCM
12
Soleus Capital Management
Connecticut
$6.46M +$8.46M +400,000 New
DCM
13
Driehaus Capital Management
Illinois
$4.88M +$6.4M +302,457 New
AAA
14
Affinity Asset Advisors
New York
$4.52M +$5.92M +280,031 New
B
15
Braidwell
Connecticut
$4.22M +$5.53M +261,504 New
Wellington Management Group
16
Wellington Management Group
Massachusetts
$2.9M +$3.52M +166,183 +1,213%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$1.63M +$1.06M +50,000 +98%
Blackstone Inc
18
Blackstone Inc
New York
$1.22M +$1.6M +75,614 New
TCM
19
Tang Capital Management
California
$809K +$1.06M +50,152 New
JFG
20
Jefferies Financial Group
New York
$437K +$449K +21,246 +363%
Morgan Stanley
21
Morgan Stanley
New York
$248K +$325K +15,342 +29,504%
Bank of America
22
Bank of America
North Carolina
$149K +$195K +9,223 +115,288%
BlackRock
23
BlackRock
New York
$97.7K -$25.6K -1,212 -17%
Barclays
24
Barclays
United Kingdom
$4.62K +$6.03K +285 +28,500%
UBS Group
25
UBS Group
Switzerland
$3.6K -$93.8K -4,436 -95%
1
2

CBIO Hedge Fund Activity: Q2 2025 in Review

30 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2025, worth a combined $174M — up 2,587% from $6.46M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CBIO and 15 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 9 added.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $29.9M. The largest seller was Vanguard Group, exiting entirely with an estimated $561K sold.

  • 30 institutional investors held Crescent Biopharma (CBIO) as of Q2 2025, down from 35 in Q1 2025.
  • Funds reported $174M of Crescent Biopharma stock for Q2 2025, up 2,587% quarter-over-quarter.
  • 15 funds opened new Crescent Biopharma positions in Q2 2025 and 20 closed out, a net change of -5 holders.
  • The largest Crescent Biopharma buyer in Q2 2025 was Fidelity Investments, an estimated $29.9M added.
  • The largest Crescent Biopharma seller in Q2 2025 was Vanguard Group, an estimated $561K sold.

Based on aggregated 13F filings for Q2 2025.